ArticleAnais brasileiros de dermatologia2019
Paraneoplastic pemphigus: a clinical, laboratorial, and therapeutic overview.
Article in Anais brasileiros de dermatologia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV).Journal of the European Academy of Dermatology and Venereology : JEADV · 2023Guideline
- Oral paraneoplastic manifestations and findings associated with extra-oral surgically treated malignancies: a prospective cross-sectional study of 300 cases.World journal of surgical oncology · 2026Article
- Paraneoplastic Pemphigus Associated With Renal Cell Carcinoma. Rare Case Report and Literature Review.Clinical medicine insights. Case reports · 2026Article
- Primary pulmonary mesenchymal malignancy associated with paraneoplastic pemphigus: a case report.Frontiers in medicine · 2026Article
- Paraneoplastic Pemphigus Unveiling Occult Lung Adenocarcinoma: A Rituximab-Responsive Case With Diagnostic and Therapeutic Implications.Clinical case reports · 2025Article
- From oral erosions to lymphoma: a case of paraneoplastic pemphigus with occult lymphoma.Oxford medical case reports · 2025Article
- Autoimmune bullous diseases: pathogenesis and clinical management.Molecular biomedicine · 2025Review
- The Importance and Challenges of Early Diagnosis of Paraneoplastic Skin Syndromes in Cancer Detection-A Review.Cancers · 2025Review
- Two Patients with Therapy-Resistant Pemphigus Vulgaris and Severe Underlying Disease Showing Good Response to a New IVIg Preparation.Dermatology and therapy · 2025Article
- Constrictive bronchiolitis and paraneoplastic pemphigus caused by unicentric Castleman disease in a young woman: a case report.Frontiers in medicine · 2024Article
- Case Report: A rare pediatric case of paraneoplastic pemphigus associated with Castleman disease misdiagnosed as Behçets disease.Frontiers in pediatrics · 2024Article
- Article
- Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.Rheumatology (Oxford, England) · 2023Review
- Recurrent pruritic polymorphic lesions associated with weight loss.JAAD case reports · 2022Article
- Mechanism of periplakin on ovarian cancer cell phenotype and its influence on prognosis.Translational cancer research · 2022Article
- Coexistence of Discoid Lupus Erythematosus and Paraneoplastic Pemphigus: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2022Article
- Toxic epidermal necrolysis-like toxic erythema of chemotherapy: 2 illustrative cases.JAAD case reports · 2021Article
- Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Pemphigus Vulgaris After COVID-19: a Case of Induced Autoimmunity.SN comprehensive clinical medicine · 2021Article
- Autoimmune disorders and paraneoplastic syndromes in thymoma.Journal of thoracic disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Paraneoplastic pemphigus is a rare and severe autoimmune blistering disease characterized by mucocutaneous lesions associated with benign and malignant neoplasms. Diagnostic criteria include the presence of chronic mucositis and polymorphic cutaneous lesions with occult or confirmed neoplasia; histopathological analysis exhibiting intraepidermal acantholysis, necrotic keratinocytes, and vacuolar interface dermatitis; direct immunofluorescence with intercellular deposits (IgG and C3) and at the basement membrane zone (IgG); indirect immunofluorescence with intercellular deposition of IgG (substrates: monkey esophagus and simple, columnar, and transitional epithelium); and, autoreactivity to desmogleins 1 and 3, desmocollins 1, 2, and 3, desmoplakins I and II, envoplakin, periplakin, epiplakin, plectin, BP230, and α-2-macroglobulin-like protein 1. Neoplasias frequently related to paraneoplastic pemphigus include chronic lymphocytic leukemia, non-Hodgkin lymphoma, carcinomas, Castleman disease, thymoma, and others. Currently, there is no standardized treatment for paraneoplastic pemphigus. Systemic corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, rituximab, cyclophosphamide, plasmapheresis, and intravenous immunoglobulin have been used, with variable outcomes. Reported survival rates in 1, 2, and 5 years are 49%, 41%, and 38%, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.